Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Amgen Colorectal Cancer Drug Gains Expanded U.S. Approval

May 23 (Bloomberg) -- Amgen Inc. won expanded U.S. approval for its drug Vectibix as an initial treatment in patients with a type of advanced colorectal cancer who first undergo genetic screening.

The drug was cleared by the Food and Drug Administration as an initial treatment in conjunction with chemotherapy for patients whose tumors have a gene mutation that renders their cancer susceptible to the medicine, the Thousand Oaks, California-based company said today in a statement. The agency also cleared Qiagen NV’s test that can show whether Amgen’s drug will be effective in patients, the companies said.

Qiagen’s product, therascreen, has now been approved for use with two drugs to fight colorectal cancer after it has spread. The test was approved in July 2012 to be used in conjunction with Bristol-Myers Squibb Co. and Eli Lilly & Co.’s Erbitux, which isn’t effective in people whose tumors have the KRAS mutation. The mutation occurs in about 40 percent of colorectal cancer patients, according to Qiagen.

“Because every patient with cancer is unique, we have made it our mission to focus on identifying treatment options for patients based on their cancer’s genetic makeup,” Sean Harper, executive vice president of research and development at Amgen, said in the statement.

The approval is “an example of the advancements that can be made through a greater understanding of distinct genetic markers associated with difficult-to-treat diseases,” Harper said.

Cancer of the colon or rectum is the third-most common type in men and women in the U.S. and the second-leading cause of cancer deaths, according to the American Cancer Society. About 137,000 new cases are expected in the U.S. this year, and more than 50,000 deaths.

Vectibix had about $389 million in sales in 2013, according to data compiled by Bloomberg. It was previously approved for use in colorectal cancer patients whose disease progressed after treatment with chemotherapy.

To contact the reporter on this story: Alex Wayne in Washington at awayne3@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Andrew Pollack, Bruce Rule

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.